MA43160B1 - Nouveaux composes de cryptophycin et conjugues, leur preparation et leur application en therapeutique - Google Patents

Nouveaux composes de cryptophycin et conjugues, leur preparation et leur application en therapeutique

Info

Publication number
MA43160B1
MA43160B1 MA43160A MA43160A MA43160B1 MA 43160 B1 MA43160 B1 MA 43160B1 MA 43160 A MA43160 A MA 43160A MA 43160 A MA43160 A MA 43160A MA 43160 B1 MA43160 B1 MA 43160B1
Authority
MA
Morocco
Prior art keywords
conjugates
preparation
therapeutic application
cryptophycin compounds
new cryptophycin
Prior art date
Application number
MA43160A
Other languages
English (en)
Inventor
Jidong Zhang
Hervé Bouchard
Antony Bigot
Marie-Priscille Brun
François Clerc
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA43160B1 publication Critical patent/MA43160B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés de cryptophycine de formule (i). L'invention concerne également les charges utiles de cryptophycine, les conjugués de cryptophycine, les compositions les contenant et leur utilisation thérapeutique, notamment comme agents anticancéreux. L'invention concerne également le procédé de préparation de ces conjugués.
MA43160A 2015-11-05 2016-11-03 Nouveaux composes de cryptophycin et conjugues, leur preparation et leur application en therapeutique MA43160B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15306751 2015-11-05
PCT/EP2016/076603 WO2017076998A1 (fr) 2015-11-05 2016-11-03 Nouveaux composés et conjugués de cryptophycine, leur préparation et leur utilisation thérapeutique
EP16791017.3A EP3371179B1 (fr) 2015-11-05 2016-11-03 Nouveaux composes de cryptophycin et conjugues, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
MA43160B1 true MA43160B1 (fr) 2019-12-31

Family

ID=54476881

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43160A MA43160B1 (fr) 2015-11-05 2016-11-03 Nouveaux composes de cryptophycin et conjugues, leur preparation et leur application en therapeutique

Country Status (35)

Country Link
US (2) US10941139B2 (fr)
EP (1) EP3371179B1 (fr)
JP (1) JP6929292B2 (fr)
KR (1) KR20180073678A (fr)
CN (1) CN108349960B (fr)
AR (1) AR106604A1 (fr)
AU (1) AU2016347724B2 (fr)
CA (1) CA3003085A1 (fr)
CL (1) CL2018001210A1 (fr)
CO (1) CO2018004581A2 (fr)
CR (1) CR20180256A (fr)
CY (1) CY1122441T1 (fr)
DK (1) DK3371179T3 (fr)
EA (1) EA035625B1 (fr)
EC (1) ECSP18034035A (fr)
ES (1) ES2755101T3 (fr)
HK (1) HK1256754B (fr)
HR (1) HRP20191729T1 (fr)
HU (1) HUE046033T2 (fr)
IL (1) IL259067B (fr)
LT (1) LT3371179T (fr)
MA (1) MA43160B1 (fr)
MX (1) MX2018005379A (fr)
MY (1) MY189448A (fr)
PH (1) PH12018500852B1 (fr)
PL (1) PL3371179T3 (fr)
PT (1) PT3371179T (fr)
RS (1) RS59498B1 (fr)
SG (1) SG11201803181SA (fr)
SI (1) SI3371179T1 (fr)
TN (1) TN2018000131A1 (fr)
TW (1) TWI714661B (fr)
UY (1) UY36979A (fr)
WO (1) WO2017076998A1 (fr)
ZA (1) ZA201802322B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI714661B (zh) 2015-11-05 2021-01-01 法商賽諾菲公司 新穎念珠藻素化合物及接合物、其製備與其治療用途
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CN110831633A (zh) * 2017-05-10 2020-02-21 赛诺菲 可用于治疗的肽类接头和念珠藻素缀合物及其制备
CN108107103B (zh) * 2017-12-14 2020-10-16 华中师范大学 谷氨酸受体的质谱探针及其在脑组织中的空间分布规律检测方法
CA3132613A1 (fr) 2019-03-07 2020-09-10 Conatus Pharmaceuticals Inc. Inhibiteurs de caspase et leurs procedes d'utilisation
US11530204B2 (en) 2019-09-30 2022-12-20 The Regents Of The University Of Michigan Biocatalytic synthesis of cryptophycin anticancer agents
EP4046996A1 (fr) 2021-02-19 2022-08-24 Universität Bielefeld Composés de cryptophycine et leurs conjugués
WO2023161291A1 (fr) 2022-02-22 2023-08-31 Araris Biotech Ag Liaisons peptidiques comprenant deux ou plusieurs charges utiles

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995017093A1 (fr) * 1993-12-21 1995-06-29 University Of Hawaii Nouvelles cryptophycines
US20020128185A1 (en) * 1998-02-25 2002-09-12 Chuan Shih Pharmaceutical compounds
US7230101B1 (en) 2002-08-28 2007-06-12 Gpc Biotech, Inc. Synthesis of methotrexate-containing heterodimeric molecules
US20050175619A1 (en) 2004-02-05 2005-08-11 Robert Duffy Methods of producing antibody conjugates
US8212083B2 (en) 2006-04-27 2012-07-03 Intezyne Technologies, Inc. Heterobifunctional poly(ethylene glycol) containing acid-labile amino protecting groups and uses thereof
EP2044122B1 (fr) 2006-07-18 2018-03-28 Sanofi Anticorps antagoniste contre epha2 pour le traitement du cancer
FR2947269B1 (fr) * 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
AR078470A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis Anticuerpos que se unen especificamente al receptor epha2
TWI714661B (zh) 2015-11-05 2021-01-01 法商賽諾菲公司 新穎念珠藻素化合物及接合物、其製備與其治療用途

Also Published As

Publication number Publication date
AU2016347724B2 (en) 2021-04-01
IL259067B (en) 2021-07-29
CO2018004581A2 (es) 2018-07-19
PT3371179T (pt) 2019-11-18
TW201730164A (zh) 2017-09-01
HUE046033T2 (hu) 2020-01-28
SI3371179T1 (sl) 2019-11-29
MX2018005379A (es) 2018-09-05
NZ741734A (en) 2023-10-27
RS59498B1 (sr) 2019-12-31
TN2018000131A1 (en) 2019-10-04
MY189448A (en) 2022-02-14
EA035625B1 (ru) 2020-07-17
CL2018001210A1 (es) 2018-08-17
JP2018535255A (ja) 2018-11-29
PL3371179T3 (pl) 2020-02-28
CN108349960A (zh) 2018-07-31
US20190382391A1 (en) 2019-12-19
CY1122441T1 (el) 2021-01-27
HK1256754B (zh) 2020-06-05
CN108349960B (zh) 2022-05-27
CA3003085A1 (fr) 2017-05-11
WO2017076998A1 (fr) 2017-05-11
SG11201803181SA (en) 2018-05-30
EP3371179A1 (fr) 2018-09-12
US10941139B2 (en) 2021-03-09
ZA201802322B (en) 2019-01-30
TWI714661B (zh) 2021-01-01
UY36979A (es) 2017-06-30
HRP20191729T1 (hr) 2019-12-13
LT3371179T (lt) 2019-11-11
US20210163458A1 (en) 2021-06-03
AR106604A1 (es) 2018-01-31
JP6929292B2 (ja) 2021-09-01
BR112018008490A2 (pt) 2019-02-12
DK3371179T3 (da) 2019-11-11
PH12018500852A1 (en) 2018-10-29
EA201890898A1 (ru) 2018-10-31
CR20180256A (es) 2018-08-13
EP3371179B1 (fr) 2019-08-07
PH12018500852B1 (en) 2018-10-29
KR20180073678A (ko) 2018-07-02
ECSP18034035A (es) 2018-05-31
ES2755101T3 (es) 2020-04-21
AU2016347724A1 (en) 2018-05-10
IL259067A (en) 2018-06-28

Similar Documents

Publication Publication Date Title
MA43160B1 (fr) Nouveaux composes de cryptophycin et conjugues, leur preparation et leur application en therapeutique
MA42230A (fr) Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA42231B1 (fr) Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant
MA43639B1 (fr) Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA42239B1 (fr) Nouveaux dérivés d'hydroxyester, leur procédé de préparation et compositions pharmaceutiques les contenant
MA41134B1 (fr) Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales
MD4584C1 (ro) (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzil)carbamoil)-2,3,4,5,7,9,13,13a-octahidro-2,5-metanopirido[1ʹ,2ʹ:4,5]pirazino[2,1-b][1,3]oxazepin-8-olat de sodiu
TR201905009T4 (tr) Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları.
MA39211A1 (fr) Composés tricycliques comme agents anti-cancers
MA45222B1 (fr) Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA33670B1 (fr) Derives de pyrrolo[2,3-d]pyrimidine
GB2511685A (en) Muscarinic m1 receptor agonists
PH12021550931A1 (en) New anthelmintic compounds
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
MD20150035A2 (ro) Inhibitori de tirozinkinaza Bruton
EA200971074A1 (ru) Антивирусные соединения
EA202090448A1 (ru) Дигидрооксадиазиноны
MX2013003635A (es) Compuestos de n-heteroarilo.
MA38803A1 (fr) Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
MA40875A (fr) 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux
MA33679B1 (fr) Derives de 2-oxo-1-pyrrolidinyle imidazothiadiazole
SG10201907291QA (en) Monomethylfumarate prodrug compositions
FR2968662B1 (fr) Nouveaux derives d'oxazaphosphorines pre-activees, utilisation et methode de preparation
MA37999B1 (fr) Dérivés de macrolide, leur préparation et leur utilisation thérapeutique
MA32061B1 (fr) Triazolopyridazines en tant qu'inhibiteurs de par1, production de celles-ci, et utilisation en tant que médicaments